Nicotinic acetylcholine receptors are key molecules in cholinergic transmission in the nervous system. Because of their structural complexity, only a limited number of subtype-specific agonists and antagonists are available to study nicotinic receptor functions. To overcome this limitation, we used voltageclamp recordings to examine the effects of several frog skin alkaloids on acetylcholine-elicited currents in Xenopus laevis oocytes expressing major types of neuronal nicotinic receptors (␣4␤2, ␣7, ␣3␤2, ␣3␤4, and ␣4␤4). We found that the 5,8-disubstituted indolizidine (Ϫ)-235B acted as a potent noncompetitive blocker of ␣4␤2 nicotinic receptors (IC 50 ϭ 74 nM). This effect was highly selective for ␣4␤2 receptors compared with ␣3␤2, ␣3␤4, and ␣4␤4 receptors. The inhibition of ␣4␤2 currents by (Ϫ)-235B was more pronounced as the acetylcholine concentration increased (from 10 nM to 100 M). Moreover, the blockade of ␣4␤2 currents by (Ϫ)-235B was voltage-dependent (more pronounced at hyperpolarized potentials) and usedependent, indicating that (Ϫ)-235B behaves as an openchannel blocker of this receptor. Several other 5,8-disubstituted indolizidines (5-n-propyl-8-n-butylindolizidines), two 5,6,8-trisubstituted indolizidines ((Ϫ)-223A and (ϩ)-6-epi-223A), and a 1,4-disubstituted quinolizidine ((ϩ)-207I) were less potent than (Ϫ)-235B, and none showed selectivity for ␣4␤2 receptors. The quinolizidine (Ϫ)-1-epi-207I and the tricyclic (ϩ)-205B had 8.7-and 5.4-fold higher sensitivity, respectively, for inhibition of the ␣7 nicotinic receptor than for inhibition of the ␣4␤2 receptor. These results show that frog alkaloids alter the function of nicotinic receptors in a subtype-selective manner, suggesting that an analysis of these alkaloids may aid in the development of selective drugs to alter nicotinic cholinergic functions.
valuable and are being investigated for possible use in these diseases (Lloyd and Williams, 2000; Dani et al., 2004) . However, selective ligands for the multiple subtypes of neuronal nicotinic receptors are still scarce.
Extracts from the skin of certain poison frogs provide a variety of pharmacologically active alkaloids, and more than 500 alkaloids have been isolated to date (Daly et al., 1999) . Some of them are known to target nAChRs: a nicotinic agonist, epibatidine, and nicotinic antagonists, histrionicotoxins, pumiliotoxins, and indolizidines (Spivak et al., 1982; Warnick et al., 1982; Aronstam et al., 1986; Daly et al., 1991 Daly et al., , 1999 . However, the selectivity of most amphibian alkaloids for each subtype of nAChR remains to be characterized. In the present study, we investigated the selectivity of bicyclic alkaloids, indolizidines, and quinolizidines, and a tricyclic alkaloid, 8b-azaacenaphthylene, across several major types of nicotinic receptors (␣4␤2, ␣7, ␣3␤2, ␣3␤4, and ␣4␤4) expressed in Xenopus laevis oocytes.
Materials and Methods
Materials. All alkaloids and their analogs used in this study were synthesized and are shown in Fig. 1 . The synthesis of indolizidine (Ϫ)-235B was performed as reported previously (Momose and Toyooka, 1994; Toyooka et al., 1997; . The structure of (Ϫ)-235B is identical to that of the natural product. The synthetic indolizidines (5-n-propyl-8-n-butylindolizidine) I, II, and III were synthesized, and indicated that 223I was not a 5,8-disubstituted indolizdine. The synthesis of indolizidine I has been shown previously (Toyooka et al., 1997; . The synthesis of 5,6,8-trisubstituted indolizidine (Ϫ)-223A along with revision of its structure has recently been reported as well as the synthesis of a 6-epimer (223A proposed). This unnatural compound has been designated (ϩ)-6-epi-223A in the present study. The 1,4-disubstituted quinolizidine (ϩ)-207I, which is the opposite enantiomer of the natural product, was synthesized in recent studies Nemoto, 2002, 2003 ). An unnatural 1-epimer of (ϩ)-207I, named (Ϫ)-1-epi-207I in this study, was synthesized as described previously (Toyooka et al., 1997; . Synthetic (ϩ)-205B is the opposite enantiomer of natural (Ϫ)-205B, as reported by .
The other reagents were purchased from Sigma (St. Louis, MO), unless indicated otherwise. BAPTA-AM was purchased from Calbiochem-Novabiochem Corp. (San Diego, CA) .
The cDNAs of the rat ␣3, ␤2, and ␤4 subunits in pcDNA1/Neo vectors were subcloned into HindIII and XhoI sites of pcDNA3.1 vectors (Invitrogen, Carlsbad, CA) , and the cDNA of the rat ␣4 subunit in pcDNA1/Neo vectors was subcloned into HindIII and XbaI sites of pcDNA3.1 vectors (Invitrogen) to enhance the expression of ␣3␤2, ␣3␤4, and ␣4␤4 nicotinic receptors in oocytes. To express ␣4␤2 and ␣7 nAChRs, mouse cDNAs were used.
Expression in X. laevis Oocytes. All experiments were carried out in accordance with guidelines approved by the Toyama Medical and Pharmaceutical University Animal Research Committee. Oocytes were surgically removed from X. laevis frogs under anesthesia using Tricaine solution (2.4 g/l). The oocytes were rinsed in calciumfree OR2 buffer (82.5 mM NaCl, 2.5 mM KCl, 1 mM MgCl 2 , and 5 mM HEPES, pH 7.6), then defolliculated in this buffer supplemented with 1.5 mg/ml collagenase A (Roche Diagnostics, Mannheim, Germany) for approximately 2 h at room temperature. Stage V-VI oocytes were selected and microinjected with 20 ng of cDNAs in the nucleus. The mixture of two subunit cDNAs, ␣3 or ␣4 in combination with ␤2 or ␤4, was injected in a ratio of 1:1, whereas ␣7 subunit was injected alone. Oocytes were incubated at 19°C in standard oocyte saline solution (100 mM NaCl, 2 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , and 5 mM HEPES, 2.5 mM pyruvic acid, 1% BSA, and 25 g/ml gentamycin, pH 7.5) for 3 to 8 days before recordings were made.
Electrophysiological Recording. An oocyte was placed in a 300-l tube-like chamber in which Ringer's solution (82.5 mM NaCl, 2.5 mM KCl, 2.5 mM CaCl 2 , 1 mM MgCl 2 , and 5 mM HEPES, pH 7.4) containing 1 M atropine to block endogenous muscarinic receptors was perfused by gravity (15 ml/min). Current responses were recorded under two-electrode voltage-clamp at a holding potential of Ϫ60 mV using a GeneClamp 500 amplifier and pClamp7 software (Axon Instruments, Union City, CA). The sampling rate was 20 Hz. Electrodes contained 3 M KCl and had resistances of Ͻ1 M⍀.
To apply a pulse of acetylcholine (ACh) to the oocyte, the perfusion fluid was switched to one containing ACh for 5 s, using a three-way Teflon solenoid valve (Parker Hannifin Corp., General Valve Division, Fairfield, NJ) controlled by a PC computer with pClamp7 software. A 3-min wash between ACh applications produced reproducible control currents with no obvious desensitization. For responses in alkaloids (test responses), the perfusion fluid was stopped during alkaloid application for 3 min to conserve the compounds. Perfusion was started again 0.5 min before measuring responses to ACh in the presence of test alkaloid.
Control experiments in the Ca 2ϩ chelator BAPTA were performed to minimize the activation of endogenous Ca 2ϩ -activated chloride channels in X. laevis oocytes. Those endogenous currents were prevented by BAPTA to be sure that they did not alter the pharmacological profiles of the tested alkaloids. Oocytes were loaded with BAPTA by incubating in a SOS solution containing BAPTA-AM (100 M) for 4 h before recording, as described previously (Ibanez-Tallon et al., 2002) . Otherwise, oocytes were incubated with a low-Ca 2ϩ Ringer's solution (82.5 mM NaCl, 2.5 mM KCl, 0.5 mM CaCl 2 , 2 mM MgCl 2 , and 5 mM HEPES, pH 7.4) to depress the endogenous chloride conductance while we investigated the mechanism of receptor blockade by the alkaloids. Data Analysis. The average peak amplitudes of three control responses to ACh (1 M for ␣4␤2 and ␣4␤4 receptors; 100 M for ␣7, ␣3␤2, and ␣3␤4 receptors) just preceding exposure to alkaloids were used to normalize the amplitude of each test response. These ACh concentrations were determined to be approximately 30% of the maximum effective concentrations (EC 30 ), according to the AChconcentration response curve (data not shown). Each data point of the concentration-response curve represents the average value Ϯ S.E.M. of measurements from at least three oocytes.
Concentration-inhibition curves for alkaloids (antagonists) were fitted by a nonlinear regression to the equation: I ϭ I max Ϫ I max /[1 ϩ (IC 50 /An) nH ], where I max is the maximal normalized current response (in the absence of antagonist for inhibitory curves), An is the antagonist concentration, IC 50 is the antagonist concentration eliciting half-maximal current, and n H is the Hill coefficient. Curve fittings were analyzed using Prism software (GraphPad Software, Inc., San Diego, CA). For antagonist efficacy curves, I max was constrained to 1 and I min was constrained to 0.
The ACh concentration-response curves for ␣4␤2 nicotinic receptors were fitted to the following two-component (double sigmoid) equation using Prism software (GraphPad Software, Inc.):
, where y is the percentage amplitude, a1 is the percentage of receptors in the high-affinity component, high and low refer to relative ACh sensitivity, x is the acetylcholine concentration, and n H is the Hill coefficient. Responses evoked by 1 mM ACh corresponded to 100% activation of the high-and low-affinity components. y max is the maximal current amplitude (percentage), normalized by the amplitude of ACh (1 mM)-evoked currents in the absence of alkaloid. Moreover, fits to a single-component (sigmoid) equation y ϭ y max ϫ [1/(1 ϩ (EC 50 /x) nH ] were performed, and relative improvements between the singlecomponent fit and the two-component fit were assessed by using GraphPad Prism to calculate the F-statistic from the ratios of the minimum sums of squares of deviations.
Statistical Analysis. The significance of differences between two groups was assessed by Student's t test, and the significance of differences between multiple groups were assessed by one-way analysis of variance followed by the Dunnet's multiple range test. Values of P less than 0.05 were considered significant.
Results
The subtype selectivity of the frog alkaloids was investigated across five recombinant nAChRs (␣4␤2, ␣7, ␣3␤2, ␣3␤4, and ␣4␤4) expressed in X. laevis oocytes. The oocytes were voltage-clamped, and application of 0.1 to 1000 M ACh elicited inward currents. When the currents were elicited by the EC 30 doses of ACh (see Data Analysis), ␣4␤2 and ␣3␤2 heteromeric receptors showed faster decay kinetics than ␤4-containing heteromeric receptors (␣3␤4 and ␣4␤4), and currents through ␣7 homomeric receptors decayed very rapidly during the ACh application (Fig. 2, A and B). These features were consistent with previous observations (Alkondon and Albuquerque, 1993; Chavez-Noriega et al., 1997; Fenster et al., 1997) . We also confirmed that the ACh responses in oocytes expressing ␣4␤2 nAChRs were inhibited by 5 M dihydro-␤-erythroidine (DH␤E, a competitive neuronal nAChR antagonist acting preferentially on non-␣7 receptor) and ␣7 nAChRs were inhibited by 10 nM methyllycaconitine (MLA, an antagonist of ␣7-containing nicotinic receptors) ( Fig. 2A) . The ␣4␤2 nAChR-mediated currents gradually recovered during a 25-min washout of DH␤E, whereas ␣7 nAChR-mediated currents were completely recovered 15 min after removal of MLA.
The responses mediated by recombinant nAChRs were blocked by most of the alkaloids used, as summarized in Table 1 . When the oocytes expressing ␣4␤2 nAChR were treated with indolizidine (Ϫ)-235B (0.3 M), the peak amplitude of the ACh-elicited currents was greatly decreased (Fig. 2B ). This blocking effect was reversible within 10 min (data not shown). Compared with the efficacy on oocytes expressing the other receptor subtypes, (Ϫ)-235B blocked the ␣4␤2 receptor-mediated responses (IC 50 ϭ 74 nM, n H ϭ 0.47 Ϯ 0.04) with 6.0-fold higher sensitivity than blockade of ␣7 receptor-mediated responses (IC 50 ϭ 442 nM, n H ϭ 0.48 Ϯ 0.05), 40.5-fold higher than that of ␣3␤2 receptor-mediated ones (IC 50 ϭ 3.0 M, n H ϭ 0.74 Ϯ 0.05), 51.4-fold higher than that of ␣3␤4 receptor-mediated ones (IC 50 ϭ 3.8 M, n H ϭ 0.49 Ϯ 0.07), and 54.1-fold higher than that of ␣4␤4 receptormediated ones (IC 50 ϭ 4.0 M, n H ϭ 0.91 Ϯ 0.10) (Fig. 2, B and C).
To exclude the possibility that indolizidine (Ϫ)-235B blocks nAChR signaling downstream, such as endogenous Ca 2ϩ -activated chloride channels that could amplify the nAChR responses in X. laevis oocytes, BAPTA control experiments were performed. Oocytes were incubated with the membrane-permeable Ca 2ϩ chelator, BAPTA-AM, before recording. Similar blocking actions of indolizidine (Ϫ)-235B were observed in the BAPTA-AM-treated oocytes expressing ␣4␤2 nAChRs. Compared with untreated oocytes, the peak amplitude of the currents elicited by ACh (1 M) in the absence of (Ϫ)-235B was 459 Ϯ 46 nA (3 oocytes), and in the presence of 0.1 and 0.3 M (Ϫ)-235B, the amplitudes were decreased to 58.0 Ϯ 3.2 and 35.7 Ϯ 6.8%, respectively. These results indicate that indolizidine (Ϫ)-235B directly blocks ␣4␤2 nAChRs.
Analysis of the ␣4␤2 peak current amplitude revealed that the ACh concentration-response curves were not adequately described by a single Hill equation (Fig. 3A , dashed line, EC 50 ϭ 10.9 M and n H ϭ 0.52). A significantly better fit was obtained with the sum of two Hill equations (Fig. 3A , continuous line), indicating the existence of a high-and low-affinity component (Zwart and Vijverberg, 1998; Covernton and Connolly, 2000; Buisson and Bertrand, 2001; Nelson et al., 2003; Almeida et al., 2004; Khiroug et al., 2004) . The high-affinity coefficients were EC 50,high ϭ 1.3 M and n H,high ϭ 0.56, whereas the low-affinity coefficients were EC 50,low ϭ 119 M and n H,low ϭ 1.5. The fractions of high-and low-affinity components were 58.3 and 41.7%, respectively. In the presence of indolizidine (Ϫ)-235B (0.1 M), the ACh concentration-response curve shifted downward, and the responses to ACh at the maximal concentration (1 mM) did not reach the levels observed in the absence of (Ϫ)-235B (Fig. 3A) . These results indicate that indolizidine (Ϫ)-235B is not acting as a competitive antagonists of ␣4␤2 receptors. The concentration-response relationship for ACh in the presence of (Ϫ)-235B was well fit by a single Hill equation (Fig. 3A , dashed line, EC 50 ϭ 8.8 M and n H ϭ 0.44). When we applied the two-component model to the data, the fit obtained is shown as the continuous line in Fig. 3A , yielding the high-affinity coefficients of EC 50,high ϭ 0.07 M and n H,high ϭ 0.85 and the low-affinity coefficients of EC 50,low ϭ 24.8 M and n H,low ϭ 1.0. The fractions of high-and low-affinity components were 31.0 and 69.0%, respectively.
To know the mode of the receptor blockade by (Ϫ)-235B, ␣4␤2 receptors were activated by increasing concentrations of ACh (ranging from 10 nM to 1 mM) in the presence of (Ϫ)-235B (0.1 M). The ACh-elicited currents were measured in a lower external Ca 2ϩ concentration (0.5 mM) to avoid the Ca 2ϩ -activated chloride conductance. As shown in Fig. 3B , the relative blockade by (Ϫ)-235B was larger at the higher concentrations of ACh. Thus, in the presence of the alkaloid (Ϫ)-235B at a constant concentration (0.1 M), the peak amplitudes of currents elicited by ACh at 0.1 and 100 M were reduced by 32.8 Ϯ 5.8 and 71.5 Ϯ 3.4%, respectively; differences were statistically significant (P Ͻ 0.01, determined by unpaired Student's t test).
Moreover, the voltage dependence of the blocking effects of (Ϫ)-235B on ␣4␤2 currents was explored at different holding potentials (from Ϫ140 to ϩ40 mV) in 20-mV steps. The currents were elicited by ACh (1 M) in 0.5 mM Ca 2ϩ . As shown in Fig. 4A , the current-voltage relationship showed strong inward rectification for the ACh (1 M)-elicited current at positive membrane potentials. Exposure to (Ϫ)-235B (0.1 M) induced a reduction of the peak amplitude of currents, and the magnitude of this reduction was more pronounced at hyperpolarized potentials. (Ϫ)-235B blocked the ␣4␤2 currents by 68 Ϯ 6% at Ϫ140 mV and by only 38 Ϯ 6% at Ϫ40 mV (Fig. 4B) .
We also investigated whether (Ϫ)-235B produces a usedependent blockade of ␣4␤2 receptors. When oocytes expressing ␣4␤2 receptors were stimulated with short pulses of ACh (10 M, 200 ms) every 8 s in 0.5 mM Ca 2ϩ , consistent, repeatable currents were obtained. Figure 5A shows a typical recording in one oocyte. In contrast, when (Ϫ)-235B (0.1 M) was superfused in the bath for 15 s preceding ACh application, then the responses to the repetitive pulses of ACh coapplied with (Ϫ)-235B (0.1 M) were progressively decreased in the same oocyte (Fig. 5A) . Figure 5B summarizes the results obtained during the first 64 s in different oocytes. We further studied whether the blocking effect of (Ϫ)-235B (0.1 M) depends on the frequency of the ACh pulses. Using a lower frequency (16-s interval) rather than 8-s interval of stimulation, we found a significant difference in the extent of the blockade of ␣4␤2 currents at the two frequencies (Fig.  5B) . At any time point tested, (Ϫ)-235B produced a stronger blockade of the currents elicited by ACh pulses at the higher frequency (8-s interval) than at the lower frequency (16-s interval). Next, we tested the effects of another type of the 5,8-disubstituted indolizidine analogs, 5-n-propyl-8-n-butylindolizidines I, II, and III, on the ACh-elicited currents in oocytes expressing recombinant nicotinic receptors. These three compounds are stereoisomers, and I has the same stereochemistry as (Ϫ)-235B at the 5 and 9 positions (5,9-cis: 5,9Z), as shown in Fig. 1 . The alkaloid I at 10 M blocked the responses mediated by ␣4␤2 receptors and ␣7 receptors similarly (Fig. 6A) . In fact, these currents were blocked by this alkaloid in a concentration-dependent manner, with IC 50 values of 6.0 M for ␣4␤2 currents and 3.4 M for ␣7 currents (Fig. 6B, Table 1 ). In contrast, the indolizidines II and III were more potent at blocking the responses mediated by ␣7 receptors than ␣4␤2 receptors (Table 1 ). In addition, the indolizidine I had a negligible effect on the ␣3␤4 receptor responses at a high concentration (10 M), whereas the responses through this receptor were substantially blocked by the indolizidine II (IC 50 ϭ 14.7 M) and were potently blocked by the indolizidine III (IC 50 ϭ 3.0 M).
Stereoselective pharmacological properties were also observed with the 5,6,8-trisubstituted indolizidines (ϩ)-6-epi-223A and (Ϫ)-223A. The alkaloid (ϩ)-6-epi-223A (10 M) had a negligible effect on the ACh-elicited currents in oocytes expressing ␣4␤2 or ␣7 receptors (Table 1) , whereas (Ϫ)-223A (10 M) blocked both the ␣4␤2 and ␣7 receptor-mediated currents to a similar extent (Fig. 7A) . (Ϫ)-223A blocked those (Fig. 7B, Table 1 ). The ␣3␤4 receptor-mediated currents were also blocked by (Ϫ)-223A with an IC 50 value of 14 M (Fig. 7, Table 1 ). This blocking effect was similar to that of (ϩ)-6-epi-223A (IC 50 ϭ 15 M).
The 1,4-disubstituted quinolizidine (Ϫ)-1-epi-207I selectively blocked ␣7 receptor responses (IC 50 ϭ 0.6 M), and it did so with 8.7-fold higher sensitivity than blockade of ␣4␤2 receptor responses (IC 50 ϭ 5.2 M) and 14.7-fold higher than that of ␣3␤4 receptor responses (IC 50 ϭ 8.8 M) ( Table 1) . The alkaloid (ϩ)-207I equally blocked the responses mediated by ␣4␤2 receptors (IC 50 ϭ 5.0 M) and ␣7 receptors (IC 50 ϭ 3.4 M).
When the oocytes expressing ␣7 nAChRs were treated with 3 M 8b-azaacenaphthylene (ϩ)-205B, which is the unnatural enantiomer, the peak amplitude of the ACh-elicited currents was greatly decreased, whereas the responses via ␣4␤2 and ␣3␤4 nAChRs were not strongly affected (Fig. 8A) . The blocking effect of (ϩ)-205B (3 M) on ␣7 nAChRs was reversible within 10 min (data not shown). When the concentrationresponse curves were compared across these nAChR subtypes, (ϩ)-205B blocked the ␣7 receptor-mediated currents (IC 50 ϭ 2.5 M, n H ϭ 0.46 Ϯ 0.08) with 5.4-fold higher sensitivity than blockade of the ␣4␤2 receptor-mediated currents (IC 50 ϭ 13.5 M, n H ϭ 0.44 Ϯ 0.05) and 4.5-fold higher than blockade of the ␣3␤4 receptor-mediated currents (IC 50 ϭ 11.3 M, n H ϭ 0.65 Ϯ 0.13) (Fig. 8B, Table 1 ). These results indicate that (ϩ)-205B selectively blocked the responses mediated by ␣7 receptors, rather than ␣4␤2 and ␣3␤4 receptors. In the BAPTA-AM-treated oocytes expressing ␣7 nAChRs, the peak amplitudes of the ACh (100 M)-elicited currents were decreased by (ϩ)-205B at 3 and 10 M to 45.7 Ϯ 6.3% and 11.7 Ϯ 0.3% (three oocytes), respectively. These results demonstrate that (ϩ)-205B directly blocks ␣7 nAChRs.
Discussion
The bicyclic "izidine" alkaloids (indolizidines, quinolizidines, pyrrolizidines, and azabicyclo[5.3.0]decanes) from amphibian skin have been examined. The alkaloids are mainly from neotropical dendrobatid frogs, Dendrobates spp., and most of the bicyclic alkaloids are known to be disubstituted, such as 5,8-or 3,5-disubstituted indolizidines and 1,4-disubstituted quinolizidines (Daly et al., 1999) . Previously, it has been shown that particular 5,8-disubsutituted indolizidines, including (Ϫ)-235B, act as noncompetitive nicotinic antagonists and inhibit carbamylcholine-elicited 22 Na ϩ -influx via nAChR channels in PC-12 cells (Daly et al., 1991) . In this study, we examined the selectivity of indoliz- idines for multiple subtypes of recombinant nAChRs expressed in oocytes. In addition, we examined the effects of several synthetic compounds with structures of frog alkaloids. Among these compounds, we found that indolizidine (Ϫ)-235B was a highly potent blocker of ␣4␤2 nAChRs (IC 50 ϭ 0.07 M). (Ϫ)-235B seems to block via direct interaction with ␣4␤2 receptors, not through an indirect effect on the oocytes' endogenous Ca 2ϩ -activated chloride channels. The concentration-response relationship for ACh on ␣4␤2 nAChRs was best fit by the sum of two Hill equations. This finding is consistent with previous reports, indicating that there are at least two different populations of ␣4␤2 nAChRs with different affinities for ACh when ectopically expressed in X. laevis oocytes (Zwart and Vijverberg, 1998; Covernton and Connolly, 2000; Khiroug et al., 2004) and in HEK293 cell lines (Buisson and Bertrand, 2001; Nelson et al., 2003; Almeida et al., 2004) . It has been proposed that these different properties are attributable to different subunit stoichiometries: the high-affinity nAChR is thought to be (␣4) 2 (␤2) 3 , whereas the low-affinity nAChR is (␣4) 3 (␤2) 2 (Nelson et al., 2003) .
The blockade of ␣4␤2 currents by (Ϫ)-235B was more pronounced as the ACh concentrations increased (from 10 nM to 100 M). If the low-affinity population of ␣4␤2 receptors were predominant compared with the high-affinity population in the present condition, selective blockade of the low-affinity receptors might explain the stronger effect of (Ϫ)-235B on the responses to higher concentrations of ACh. In fact, the populations were almost equal between the highaffinity component (58.3%) and the low-affinity component (41.7%) based on the analysis of the ACh concentrationresponse curve (Fig. 3A) . Furthermore, we estimate that activation of the high-and low-affinity receptors contributed to 58% and 42%, respectively, of the peak currents elicited by 1 M ACh. The alkaloid (Ϫ)-235B (0.1 nM-10 M) blocked the ACh-elicited (1 M) currents, and the concentrationresponse relationship for (Ϫ)-235B was well described by a single sigmoid curve (Fig. 2C) , without requiring a double sigmoid, indicating that (Ϫ)-235B did not significantly differentiate between the high-and low-affinity receptors. Thus, the mode of action of (Ϫ)-235B seems to be independent of these receptor populations. Because the probability of the ␣4␤2 nAChR-channel opening increases as the ACh concentration increases, (Ϫ)-235B blocks the receptor-channels that are more frequently open at higher ACh concentrations by entering and occluding the open-channel pores. In general, open channel blockers are known to exhibit both a voltage-dependent and a use-dependent inhibition of nAChRs (Buisson and Bertrand, 1998; Pintado et al., 2000) . Consistent with that expectation, we observed that (Ϫ)-235B exerted stronger inhibition of the ␣4␤2 currents at hyperpolarized potentials. In addition, the ␣4␤2 currents elicited by repetitive ACh pulses were progressively inhibited by (Ϫ)-235B in a use-dependent manner. Therefore, the mode of action of (Ϫ)-235B is likely to be open channel blockade.
The sensitivity of indolizidine (Ϫ)-235B for ␣4␤2 receptors was comparable with that of the best characterized antago- nist of ␣4␤2 nAChRs, DH␤E, observed in X. laevis oocytes expressing human ␣4␤2 receptors (IC 50 ϭ 0.11 M) (ChavezNoriega et al., 1997) . Moreover, (Ϫ)-235B selectively blocked ␣4␤2 receptors more effectively than ␣3␤2 receptors (40.5-fold) or ␣3␤4 receptors (51.4-fold). These pharmacological properties are also comparable with DH␤E. However, the selectivity for ␣4␤2 receptors over ␣7 or ␣4␤4 receptors was different between (Ϫ)-235B and DH␤E: the rank order of potency of (Ϫ)-235B was ␣4␤2Ͼ␣7Ͼ␣3␤2Ͼ␣3␤4Ϸ␣4␤4, whereas that of DH␤E is ␣4␤4Ͼ␣4␤2Ͼ␣3␤2Ͼ␣3␤4Ϸ␣7 (Chavez-Noriega et al., 1997). It may be possible to develop even more potent and selective ligands on the basis of the structure of indolizidine (Ϫ)-235B.
The structure of natural 5,6,8-trisubstituted indolizidine (Ϫ)-223A has recently been revised from (ϩ)-6-epi-223A . It is interesting that (Ϫ)-223A but not (ϩ)-6-epi-223A exhibited blocking effects on ␣4␤2 and ␣7 receptors. These results suggest that the alkaloid (Ϫ)-223A may bind to the nAChRs in a stereoselective manner.
We also examined the stereoselective pharmacological properties of three stereoisomers, 5,8-disubstituted indolizidines I, II, and III. The indolizidine I has a 5,9-cis (5,9Z) structure, whereas the other two compounds have 5,9-trans (5,9E) structures. Because the indolizidine I exhibited a greater sensitivity to ␣4␤2 receptors than the indolizidines II and III, the 5,9-cis (5,9Z) structure may be important for binding to ␣4␤2 receptors with high affinity. Indeed, indolizidine (Ϫ)-235B that possesses the 5,9-cis (5,9Z) structure was a potent blocker of ␣4␤2 receptors, as mentioned above. To test this hypothesis, it would be necessary to examine the effect of the (Ϫ)-235B stereoisomer with a 5,9-trans (5,9E) structure on ␣4␤2 receptors in a future study.
The alkaloid (ϩ)-205B has a unique tricyclic structure of 8b-azaacenaphthylene (Daly et al., 1999) . No other alkaloids from amphibian skin are known to belong to this class. The absolute stereochemistry of this alkaloid was determined by the total synthesis . The alkaloid (ϩ)-205B produced a selective inhibition of ␣7 receptors over ␣4␤2 or ␣3␤4 receptors. We also found the high selectivity (8.7-fold) of 1,4-disubstituted quinolizidine (Ϫ)-1-epi-207I for ␣7 receptors over ␣4␤2 receptors, which is greater than the ␣7 selectivity (5.4-fold) of (ϩ)-205B. Therefore, we suggest that a novel class of nicotinic antagonists may be developed based on the structure of these compounds.
In conclusion, we found that indolizidine (Ϫ)-235B is a potent noncompetitive blocker of ␣4␤2 nAChRs, and its specificity is comparable with that of the competitive antagonist DH␤E. We also found that quinolizidine (Ϫ)-1-epi-207I and tricyclic (ϩ)-205B are selective blockers of ␣7 nAChRs. It should also be noted that some of the alkaloids used in this study exhibited subtype-selective blockade of nAChRs in a stereoselective manner. These results suggest that it may be possible to obtain novel, potent, and subtype-selective blockers of nicotinic receptors by synthesizing stereoisomers of natural alkaloids. Thus, it is anticipated that the approach based on the frog alkaloids can provide lead compounds for the future design of drugs to treat cholinergic disorders in the central nervous system.
